Minimally Invasive Bariatric Surgery Equipments Market Scope
Minimally invasive bariatric surgery equipment includes the use of various types of devices during the procedure. This equipment includes gastric band, gastric bypass, adjustable gastric band, sleeve gastrectomy, and biliopancreatic diversion. The major factor attributing to the demand for minimally invasive bariatric surgery equipment are, increase in the number of obese population, sedentary lifestyle, and increasing demand for minimally invasive weight loss surgery. Moreover, people are more concerned about their physical appearance this will attract the pool of people to undergo minimally invasive bariatric surgery procedures.
Attributes | Details |
---|
Study Period | 2018-2030 |
Base Year | 2023 |
Unit | Value (USD Million) |
Key Companies Profiled | Medtronic plc (Ireland), Apollo Endosurgery Inc. (United States), Aspire Bariatrics Inc. (United States), Ethicon Inc. (United States), ReShape Lifesciences (United States), Olympus Corporation (Japan), Integra Life Sciences Holding Corporation (United States), Allergan (Ireland), Covidien Plc (Ireland) and Silimed Ltd (Brazil) |
CAGR | 3.5% |
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches, and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA estimates that Global Players will contribute to the maximum growth of Global Minimally Invasive Bariatric Surgery Equipments market throughout the predicted period.
Medtronic plc (Ireland), Apollo Endosurgery Inc. (United States), Aspire Bariatrics Inc. (United States), Ethicon Inc. (United States), ReShape Lifesciences (United States), Olympus Corporation (Japan), Integra Life Sciences Holding Corporation (United States), Allergan (Ireland), Covidien Plc (Ireland) and Silimed Ltd (Brazil) are some of the key players that are part of study coverage.
About Approach
The research aims to propose a patent-based approach in searching for potential technology partners as a supporting tool for enabling open innovation. The study also proposes a systematic searching process of technology partners as a preliminary step to select the emerging and key players that are involved in implementing market estimations. While patent analysis is employed to overcome the aforementioned data- and process-related limitations, as expenses occurred in that technology allows us to estimate the market size by evolving segments as target market from the total available market.
Segmentation Overview
The study have segmented the market of Global Minimally Invasive Bariatric Surgery Equipments market by Type , by Application (Bariatric Surgical Centers, Hospitals, Plastic Surgery and Other) and Region with country level break-up.
On the basis of geography, the market of Minimally Invasive Bariatric Surgery Equipments has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico).
region held largest market share in the year 2023.
Market Leaders and their expansionary development strategies
In March 2023, Teleflex Incorporated announced a supply agreement with W. L. Gore & Associates, Inc. (Gore) to use Gore’s GORE SEAMGUARD Bioabsorbable Staple Line Reinforcement material in a staple line reinforcement device designed by Teleflex for use with the Titan SGS Powered Stapling Device. With these two innovative technologies paired together, bariatric surgeons will be able to utilize the advanced technology of the Titan SGS Device with GORE SEAMGUARD Bioabsorbable Staple Line Reinforcement material. Teleflex will provide specifics around future product commercialization dates.
In February 2024, BariaTek Medical, a privately held medical device company dedicated to the development of minimally invasive endoscopically delivered solutions to treat obesity and diabetes, founded by Truffle Capital, announced it has initiated enrollment of patients in its First-in-human clinical trial in both Australia and Uzbekistan, and has successfully performed its first-in-human implantation.
Influencing Trend:
High Investments In Healthcare R&D
Market Growth Drivers:
Increasing Incidences Of Chronic Diseases and Increasing Aging Population
Challenges:
Fierce Competitive Pressure
Restraints:
Medical Device Industry's Uncertain Regulatory Framework
Opportunities:
High Governmental Healthcare Expenditure
Key Target Audience
Minimally Invasive Bariatric Surgery Equipments Provider, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others